Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basel Medical GroupBMGL -10.42%17 Return-on-Tangible-Equity is 9.14% as of Dec. 2025, which is 74% below its 10-year median of 35.47. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 580 Healthcare Providers & Services companies, Basel Medical Group ranks worse than 94.66% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Basel Medical Group's annualized net income for the quarter that ended in Dec. 2025 was $0.42 Mil. Basel Medical Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $4.55 Mil. Therefore, Basel Medical Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 9.14%.
The historical rank and industry rank for Basel Medical Group's Return-on-Tangible-Equity or its related term are showing as below:
BMGL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -168.69 Med: 35.47 Max: 53.38
Current: -162.38
During the past 4 years, Basel Medical Group's highest Return-on-Tangible-Equity was 53.38%. The lowest was -168.69%. And the median was 35.47%.
BMGL's Return-on-Tangible-Equity is ranked worse than 94.66% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.085
vs BMGL: -162.38
Basel Medical Group (NAS:BMGL) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Basel Medical Group Return-on-Tangible-Equity Related Terms
Basel Medical Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Basel Medical Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basel Medical Group Return-on-Tangible-Equity Chart
BMGL vs AMS, HLYK, BICX: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Basel Medical Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basel Medical Group Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Basel Medical Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.14% mean?
Basel Medical Group (BMGL) has a Return-on-Tangible-Equity of 9.14% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Basel Medical Group and its competitors. This is 74% below median its historical median of 35.47. According to the industry distribution chart, Basel Medical Group ranks #549 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 94.7%.
Is Basel Medical Group's Return-on-Tangible-Equity too high?
Basel Medical Group's current Return-on-Tangible-Equity of 9.14% is 74% below median its 10-year median of 35.47. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.09. Basel Medical Group's value of 9.14% is 9.4% below this industry median. Based on the distribution chart, Basel Medical Group ranks #549 out of 580 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's Return-on-Tangible-Equity compare to AMS and HLYK?
According to the Healthcare Providers & Services industry distribution chart, Basel Medical Group ranks #549 out of 580 companies for Return-on-Tangible-Equity. This places Basel Medical Group in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.09. Basel Medical Group's value of 9.14% is 9.4% below this benchmark. While the company's 10-year median is 35.47 vs. the industry median of 10.09, Basel Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.09, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basel Medical Group's current Return-on-Tangible-Equity of 9.14% is 9.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Basel Medical Group and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basel Medical Group's current Return-on-Tangible-Equity is 9.14%, which is 74% below median its own 10-year median of 35.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current Return-on-Tangible-Equity of 9.14%. The current Return-on-Tangible-Equity is 9.14%, which is 74% below median its 10-year median of 35.47 and 9.4% below the Healthcare Providers & Services industry median of 10.09. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current Return-on-Tangible-Equity is 9.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score
Get the complete analysis for BMGL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMGL has been successfully added to your 
